the present invention relates to a polymer bone cement or a derivative thereof having improved mechanical properties that is adapted to bone or osteoporotic bone . in one embodiment of the invention , the polymer bone cement is pmma . the improved mechanical properties are achieved by adding a fully miscible solvent that does not react with the pmma to the reactive mma monomer . by doing so , the crosslink density of the material and the stiffness can be reduced . the present invention is based on using a substance that is fully miscible with the monomer and is , therefore , molecularly dissolved in the pmma after polymerization . however , due to its non - reactivity , this leads to a reduction in the final crosslink density and / or to a material with a microporous structure and , therefore , the stiffness of the material is reduced . after implantation and full polymerization of the material , the crosslink - lowering substance may be gradually substituted by body fluids . this concept was tested by substituting different amounts of the reactive monomer with n - methyl - pyrrolidone ( nmp ), which does not contribute to the polymerization reaction . subsequent mechanical testing of pmma samples produced in this way showed a reduction in stiffness greater than about 50 % in some embodiments . the described effect of lowering the stiffness of the material can be obtained with any solvent that is miscible with the monomer of pmma but does not contribute to the polymerization reaction . another example of such of a solvent is dimethyl - sulfoxide ( dmso ). in other embodiments , a range of other solvents can also be envisioned . in another embodiment , substances such as peg , cellulose , cellulose derivates or mixtures thereof can be added . furthermore , the present concept is not limited to pmma cements , it can be applied to a wide variety of derivatives of pmma , e . g . modifications in which styrene groups are built into the polymer backbone . the same concept also applies to cements that are not based on the acrylate chemistry . a material as described above , with mechanical properties adapted to those of e . g . osteoporotic bone can be used in any indication , where bone needs to be augmented , e . g . the proximal femur , the proximal humerus , long bones , vertebral bodies or the like . as shown by the data in table 1 , the bone cements according to embodiments of the present invention that include nmp exhibit a decrease in stiffness when compared to the bone cement without nmp . the decrease in stiffness occurs as a result of the substitution of some of mma monomer by nmp . according to some embodiments , by substituting a part of the reactive liquid mma monomer with non - reactive organic solvent nmp during polymerization , the crosslink density in the final material was lowered and therefore the stiffness of the material was reduced . in other embodiments , the nmp can act as a pore forming phase , resulting in bone cement having a microporous structure . as discussed above , a decrease in stiffness is an efficient way to reduce the risk of adjacent vertebral body fractures in vertebroplasty procedures . in some embodiments , the bone cements including nmp demonstrate an increase in hardening time . that is , the time for the bone cement to set and harden is longer for the cements having an nmp component . in some embodiments , an increase in handling time allows for greater working time for the user , which can increase the safety of surgical procedures . in addition to the reduced stiffness , another property which is influenced by the mentioned modification is the maximum polymerization temperature of the exothermic polymerization of pmma . typically , polymerization of the pmma can generate enough heat and increase the temperature of the bone cement to such a degree as to cause tissue necrosis . because the bone cements of the present invention includes a lower content of monomer ( mma ), which is the component that generates the heat during the polymerization reaction , the maximum polymerization temperature can be lowered . this is particularly advantageous because tissue necrosis may be reduced or avoided when the bone cement of the present invention is used , which allows for the use of the bone cement in areas of the body which are particularly sensitive to heat . for example , bone necrosis or other tissue necrosis can be a substantial problem during cranial reconstruction where the bone cement may contact the dura mater , due to the delicacy of the tissues and bone structures . use of a bone cement having reduced heat generation is therefore particularly desirable in these areas . another advantage of the bone cements of the present invention is the potential reduction in the toxicity of the composition . bone cement monomers , including methyl methacrylate , give off toxic vapors which can be irritating to the eyes and respiratory system . furthermore , acrylate monomers can irritate the skin , and contact with minute concentrations can cause sensitization . therefore , since the bone cement of the present invention uses a lower amount of monomer , the potential for the above problems to occur while using the bone cement of the present invention may be reduced . in some embodiments of the present invention , the bone cement can be useful for vertebroplasty . the mentioned properties of hardening behavior , mechanical and thermal properties especially increasing of the handling time ( more time for the surgeon and therefore more safety ), lowering the stiffness ( avoiding the mechanical property mismatch of the bone to the cement ) and reducing the polymerization temperature ( reduce tissue necrosis ) are important properties for cement used in vertebroplasty . it is possible , that all of these requirements could be achieved by substituting some of the mma monomer with nmp . the following example was carried out using commercial pmma cement vertecem . vertecem is a fast setting , radiopaque acrylic bone cement for use in percutaneous vertebroplasty . the fluid phase is composed of 97 . 6 % methyl - methacrylate ( mma ), 2 . 4 % n , n - dimethyl - p - toluidine as activator and very small quantities ( 20 ppm ) of hydroquinones as stabilizer . the polymer powder is composed of 64 . 4 % pmma , 0 . 6 % benzoyl peroxide which initiates the polymerization , 25 % barium sulfate as radiopaque agent and 10 % hydroxyapatite . the fluid mma monomer phase was partly substituted by nmp organic solvent by different amounts . nmp is totally miscible with the mma monomer fluid . the amounts of mma , and nmp , and pmma used in the different compositions are listed in table 1 . the mma monomer and nmp was premixed to form a fluid mixture . subsequently the fluid mixture was mixed with the pmma powder to form a paste . to prepare the samples for mechanical testing , the paste was filled into cylindrical teflon ® molds ( 20 mm height , 6 mm diameter ). the hardened cylinders were then removed from the mold , sawed and ground to the length of 12 mm , these dimensions correspond to the requirements of standard iso 5833 . after storing the samples in water for 6 days at room temperature they were submitted for mechanical compression testing according to standard iso 5833 . the elastic modulus and yield strength were determined according to the mentioned standard and presented in fig1 . results are shown in fig1 , illustrating trends versus percent of mma that is substituted by nmp . for the investigation of the hardening behavior of the cement compositions , 3 ml of the mixed bone cement were placed in a rotational rheometer with a custom designed double gap measurement system and rheological data were recorded directly to a computer for 24 portions of cement . the real ( fluid - like ) part of complex viscosity vs . time data are presented in fig2 .